ESMO Breast 2020 | HER2 blockade in HER2-E induces low-proliferative luminal A phenotype

Aleix Prat • 14 May 2020

ESMO Breast 2020

Breast Cancer Antibodies Lapatinib Trastuzumab

PAMELA Immuno-Oncology

Aleix Prat, MD, PhD, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain, discussed the phenotypic changes of HER2+ breast cancer during and after dual HER2 blockade. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Beyond HER2: dissecting tumor heterogeneity

Aleix Prat • 14 May 2020

Molecular heterogeneity in HER2+ breast cancer and predicting outcomes

Aleix Prat • 7 Dec 2021

HER2-E pCR with anti-HER2-based neoadjuvant therapies

Aleix Prat • 18 May 2020

CORALLEEN: kicking chemo?

Aleix Prat • 14 May 2020

Related Videos

Highlights in breast and gynecological cancer at ESTRO 2022

Pedro Lara • 17 May 2022

What impact will biosimilars have on clinical life?

Diana Lüftner • 21 Sep 2017

Drug shortages around the world: why communication is key

Fatima Cardoso • 22 Sep 2017

HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019